Conigen’s Apelin receptor (APLNR)-specific mouse mAb targeting the 30aa N-terminal domain can potently bind the full length human APLNR expressed on live cells by flow cytometry and the N-terminus antigen by ELISA. APLNR (UniProt# P35414), also known as the APJ receptor, plays a critical role in cardiovascular, metabolic, and developmental processes.

It is activated by endogenous peptide ligands, primarily apelin and ELABELA (also called Toddler), which bind to the receptor and trigger intracellular  pathways. Dysregulation of the apelin–APLNR system has been linked to diseases such as heart failure, hypertension, diabetes, and obesity. Because of its wide physiological relevance, APLNR has emerged as a promising therapeutic target. APLNR antibodies are available in monoclonal, polyclonal, and recombinant formats for applications including Western blot, immunohistochemistry, immunofluorescence and ELISA. 

Very limited antibodies are available for live cell staining by flow cytometry. Selection depends on application, species reactivity, epitope accessibility, and validation data. Conigen’s APLNR-specific live cell staining antibody provides an important tool to study the APLNR target expression on live cells including primary cells and transfected cells for research and drug discovery, supporting studies of receptor expression, localization, and pharmacological modulation.